Mr. TUNC MERT SAYIN addressed the opening ceremony of the Training Workshop on Monkeypox Diagnosis Using Real Time PCR Technique held by Africa Centers for Disease Control and Prevention in collaboration with Nigeria Center for Disease Control (Nigeria CDC) and Africa Society for Laboratory Medicine (ASLM).
On 17 June, the WHO released its latest update on the Monkeypox outbreak situation. The sharp growth of confirmed cases during the last two months indicates increasing uncertainty of the endemic progress. Between 1 January and 15 June 2022, a cumulative total of 2103 laboratory confirmed cases, one probable case, and one death were laboratory-confirmed had reported to WHO from 42 countries in five WHO Regions. The majority of cases (98%) have been reported since May 2022. Most cases are recognized and reported from European countries, followed by the American region.
Today, we Bioperfectus are proud to announce that STC-96A and STC-96A PLUS Real-Time PCR Systems have been listed with the U.S. Food and Drug Administration (FDA) for IVD testing. With FDA registration, Bioperfectus Real-Time PCR Systems obtained access to PCR laboratories in the US. With stable performance and user-friendly design, STC-96A and STC-96A Plus will be great helpers for molecular laboratories to identify the virus and bacterial.
Monkeypox, a rare zoonotic infectious disease caused by the monkeypox virus, is mainly spread in endemic countries in Africa. However, things seem to become different in recent days. After 20 days since the first case outside endemic countries was spotted in the UK on 2022 May 7, a cumulative total of 257 laboratory-confirmed cases and around 120 suspected cases in non-endemic countries from 23 WHO member states have been reported, according to the lasted update by WHO. Meanwhile, WHO also expects that there will be more cases identified as the surveillance expands in more and more regions.
Recently, our esteemed customer, the No.(1) Defence Services General Hospital (1000-Bedded) in Yangon, Myanmar, published their research on the Breakthrough infections due to SARS-CoV-2 Wild type, the Delta variant and the Omicron variant in early fourth wave of epidemics in Myanmar. The paper was published in February 2022 on the International Journal of Medical Science and Clinical Research Studies (Impact Factor: 5.276).